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Disclaimer:Thisguidelineisdesignedprimarilyasaneducationalresourceformedicalgeneticistsandotherhealthcareproviders
to help them provide quality medical genetics services. Adherence to this guideline does not necessarily assure a successful medical
outcome. This guideline should not be considered inclusive of all proper procedures and tests or exclusive of other procedures and
tests that are reasonably directed to obtaining the same results. In determining the propriety of any specific procedure or test, the
geneticistshouldapplyhisorherownprofessionaljudgmenttothespecificclinicalcircumstancespresentedbytheindividualpatient
or specimen.
The autism spectrum disorders are a collection of conditions, which have, in common, impaired socialization and
communication in association with stereotypic behaviors. The reported incidence of autism spectrum disorders has
increased markedly over the past decade. In addition, a large amount of attention has been paid to these
conditions among lay and professional groups. These influences have resulted in a marked increase in the number
of referrals to clinical geneticists for evaluation of persons with autism spectrum disorders. The primary role of the
geneticist in this process is to define etiology, if possible, and to provide counseling and contribute to case
management based on the results of such investigations. In deciding upon the appropriate evaluation scheme for
a particular patient, the geneticist must consider a host of different factors. Such considerations would include (1)
Assuring an accurate diagnosis of autism before proceeding with any investigation. (2) Discussing testing options,
diagnostic yields, and patient investment before proceeding with an evaluation. (3) Communication and coordina-
tion with the patient’s medical home. (4) Assessing the continuously expanding and evolving list of available
laboratory testing modalities in light of evidence-based medicine. (5) Recognizing expanded phenotypes of
well-described syndromic and metabolic conditions that encompass autism spectrum disorders. (6) Defining an
individualized evaluation scheme based on the unique history and clinical features of a given patient. The
guidelines in this article have been developed to assist the clinician in the consideration of these factors. Genet
Med 2008:10(4):301–305.
Autismspectrumdisorders(ASDs),alsoknownaspervasive
developmental disorders (PDD), are a behaviorally defined
group of neurodevelopmental disorders that are usually diag-
nosed in early childhood. They are characterized by varying
degrees of restrictions in communication and social interac-
tion and by atypical, repetitive behaviors. The phenotype of
ASDsisextremelyheterogeneouswithdifferencesfromperson
to person in a wide range of symptoms and severity as well as
differencesbetweenthevarioussubtypesofASDs(e.g.,autistic
disorder, Asperger, PDD [NOS]).
Multiplelinesofepidemiologicevidencesupportthestrong
role of genetics in the etiology of ASDs.1–3 Results of popula-
tion studies of unselected cases of autism are consistent with
multifactorialinheritance.Thereportedrecurrenceriskforfull
siblingsis4%iftheaffectedchildisagirland7%iftheaffected
child is a boy. Overall, 2–3% of families have more than one
affectedchild(potentiallybecauseofadecreasedoccurrenceof
subsequent pregnancies). If a second child has autism, the re-
currenceriskisontheorderof25–35%.Thecalculatedrelative
recurrence risks are 22.3 for autism and 13.4 for Asperger syn-
drome. The sibling risk ratio (s) is estimated to be 100–150.
Thecalculatedheritability(theproportionofphenotypicvari-
ance explained by the genotype) is around 90%. There is an
excess of twins reported in affected sib pairs. Population stud-
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Genetics IN Medicine 301ies show a concordance of 70% in monozygotic twins; 90% if
thebroaderphenotypicdefinitionisused.Thisisincontrastto
a 3% concordance in dizygotic twins.2–5
Asagroup,ASDsoccurthreetofourtimesmorecommonly
in men. Such a sexual dimorphism suggests that X-linked
genes play a major role in the etiology of the spectrum. How-
ever, whole genome screens have found only four minor link-
ages to the X chromosome, and X chromosome genes seem to
account for a only a small portion of the overall genetic con-
tribution. Evidence of linkage has been found to most auto-
somes, suggesting marked genetic heterogeneity. The most
consistently reported linkages have been with chromosomal
locations 15q11-13, 7q 22-31 (two loci with parent of origin
effect), 13q, 17q 11 (male-specific locus), 2q, and 16p.6–11
Over the past decade, the reported incidence of ASDs has
increased markedly with some estimates suggesting a quadru-
pling in 10 years. The current estimates for autism are now
reportedtobeontheorderof10–60per10,000individuals,if
allformsofASDsareconsidered.Infact,theCenterforDisease
Control and Prevention has recently estimated the prevalence
of ASDs in the United States at approximately 5.6 per 1000 (1
of 155 to 1 of 160) children.12,13 This rise in the reported prev-
alenceofASDsisunlikelytorepresentatrue“epidemic”ofthe
conditionashasbeensuggestedbysome.Rather,itseemsthat,
this reported increase can be attributed to better knowledge of
the disease and its variability, broader diagnostic criteria, im-
provedpublicandprofessionalawareness,andahigherlevelof
acceptance of the diagnosis.
Theroleoftheclinicalgeneticististodeterminetheetiology
of the ASDs, if possible, and to provide counseling for the
family. In recent years, there has been an explosion of new
diagnostic options and tools available to the clinician. Several
recent publications have also reported a host of “expanded
phenotypes” for genetic and metabolic conditions in associa-
tion with ASDs phenotypes.14–19 These factors have led to an
increaseinthenumberofreferralstotheclinicalgeneticistand
anincreaseinthediagnosticyield.Now,morethanever,med-
ical genetics services are available to help families answer the
question “Why?”
In deciding upon an evaluation plan, the clinical geneticist
has the difficult task of balancing an ever-expanding list of
available tests and possible diagnoses with the issues of cost,
practicality, and expected yield. The guidelines put forth here
outline a strategy of a tiered evaluation of the etiology of au-
tism.Theserecommendationsuseevidence-basedconclusions
from the current available literature and cumulative clinical
experience.
RATIONALE FOR AN EVALUATION
The rationale for a clinical genetics evaluation for persons
with ASDs has been questioned by some. Concerns have been
expressedoverthehighcostofsuchanevaluationcoupledwith
thefactthattheinformationobtainedtypicallywillnotchange
interventions for the patient. The rationale for performing a
clinicalgeneticsconsultationforapatientwithanASDisclear
to the clinical geneticist. Clinical geneticists can contribute to
the process by examining and evaluating the patient, the par-
ents, and siblings, as necessary, in establishing the etiology. A
definitive diagnosis helps the patient acquire needed services,
andishelpfulinmanyotherwaysforthefamily.Manyfamilies
are greatly empowered by knowledge of the underlying cause
of a relative’s disorder. Depending on the etiology, associated
medical risks may be identified that lead to screening and the
potential for prevention of morbidity. Specific recurrence risk
counseling—beyond general multifactorial information—
canbeprovided,andtargetedtestingofatriskfamilymembers
can be offered. In a limited number of cases (e.g., metabolic
disorders) targeted therapies may be or become available.
These significant positive benefits strongly justify a medical
genetics consultation for all patients with ASDs. One of the
best strategies for integrating clinical genetics services into the
care of patients with ASDs can be the participation of the ge-
neticistonaninterdisciplinary“autismteam.”Thisallowsthe
geneticisttoworkalongsideotherprofessionalsinvolvedinthe
care of persons with ASDs with access to detailed, specific di-
agnostic information about the patient.
REPORTED APPROACHES AND YIELDS
The generally reported rate of success for identifying a specific
(unifactorial) diagnosis in persons with autism is 6–15%.20–22
This range is applicable even for evaluations of patients with
PDD (NOS), atypical autism, Asperger syndrome, or autistic
features, which did not necessarily meet the Diagnostic and
Statistical Manual of Mental Disorders, 4th Edition, criteria for
PDD. Many factors seem to influence the diagnostic yield.
The use of newer diagnostic modalities and the aggressive-
ness of the evaluation seem to be the most critical. Not
surprisingly, the skill and experience of the geneticist also
factor heavily into the yield.
A critical review of the potential contribution of newer test-
ing techniques suggests that yield can be significantly higher
than 15%. Chromosomal studies are consistently reported as
giving one of the highest diagnostic yields in persons with
ASDs.23–25 Continued improvements in cytogenetic approaches
including higher resolution studies have further increased the
diagnostic yield.
Numerous submicroscopic deletions and duplications have
beenreportedinassociationwithanautismphenotype.Ingen-
eral, the most commonly reported loci mirror the reported
linkage data. Some of the most frequently reported regions
with abnormalities in association with ASDs include 15q peri-
centromeric11–13 region, 17p11, 22q11, 22q13, and 2q37. Most
recently, changes in the 16p11.2 region have been reported as
occurring in a significantly high frequency in patients with
ASDs—promptingthedesignationofthisregionasa“hotspot
of genetic instability.”26–28
Currently, array comparative genomic hybridization (aCGH)
has emerged as a powerful new tool that promises further rev-
olution of clinical genetic testing. The technology of assessing
submicroscopic rearrangements is evolving at a mind-bog-
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than clinical studies can define their use. The availability of
multiple platforms further complicates the ability to compare
studies from various sites. Relatively few studies have been
published that provide an actual estimate of the diagnostic
yield of aCGH in evaluating patients with autism. One study
found a 27.5% yield in the study of aCGH in patients with
“syndromic ” autism.29 Preliminary data from many sites sug-
gests that the cumulative yield of aCGH will prove to be the
highest yield test that is clinically available. If the estimates of
the frequency of the most commonly reported anomalies are
pooled, current aCGH platforms can be estimated to identify
abnormalities on the order of 10%, beyond what would be
identified by standard chromosomal testing (G. Schaefer, un-
published data). Until definitive, large-scale studies provide
confirmation of the use of aCGH, its role in the evaluation of
ASDs may not be fully appreciated. Realistic predictions sug-
gest that the time in which this will occur may be just a few
years.
The strong association of autism with Fragile X syndrome
hasbeenconfirmedinalmosteverylargereportedseries.15,30,31
Mutations in the Methyl-CPG-Binding Protein 2 (MECP2)
gene are reported in a significant number of women with au-
tism.20,32 To date, no male with idiopathic autism has been
reportedwithamutationintheMECP2gene.Mutationsinthe
phosphataseandtensinhomolog(PTEN)genearereportedto
occur frequently in the subgroup of patients with autism with
a head circumference 2.5 SDs greater than age-appropriate
means.14Clinicallyrecognizablesyndromesandmetabolicdis-
orders are other identifiable causes.33
A synthesis of the published literature suggests that the fol-
lowingdiagnosticyieldswouldbeprojectedinthegeneticeval-
uation of ASDs:
● High-resolution chromosome studies (5%)
● aCGH—beyond what would be detected by chromo-
somal analysis (10%)
● Fragile X (5%)
● MECP2 (5%—women only)
● PTEN (3%—if head circumference 2.5 SDs)
● Other (10%)
Thus, using current knowledge and technology, a thorough
clinical genetics evaluation of persons with ASDs will result in
a positive answer in up to 40% of individuals.
EVALUATION SCHEME
The first (and most critical) step in the clinical genetic eval-
uation of ASDs is the pre-evaluation. Several pieces of critical
information need to be obtained before beginning any inves-
tigation. An accurate ASD diagnosis is mandatory. The diag-
nosisofASDsshouldbemadebyappropriatelytrainedprofes-
sionals using objective criteria. Normal hearing should be
documented because children with significant hearing loss
tendtohavedifficultieswithsocializationandcommunication
thatmaybemisidentifiedasautism.Recentlypublishedguide-
lines from the American Academy of Pediatrics suggest that
primary care providers obtain chromosome and Fragile X
studies at the time an ASD is diagnosed.34 Thus, part of the
evaluationmayalreadyhavebeenaccomplishedbeforereferral
to the geneticist.
As with all clinical evaluations, an etiologic evaluation must
be tailored to the individual patient. The design of the evalua-
tion must take into consideration focused information from
the history and physical as well as clinical experience. There is
nosingleapproachoralgorithmthatcanbeappliedtoallcases.
Forpracticalreasons,astep-wise(tiered)evaluationisconsid-
ered by many to be the preferred approach. In general, a non-
tiered evaluation in which a large battery of tests is ordered as
part of the initial testing scheme is poorly tolerated by the
patient and family and less acceptable to third-party payers. A
stepwiseevaluationcanbedesignedsuchthattestsobtainedin
higher (earlier) tiers have a greater expected diagnostic yield,
lower invasiveness of testing, better potential of intervention,
andeasieroverallpracticality.33Amodelforsuchatieredeval-
uation is provided in Table 1.
This scheme will evolve with continued advancements in
diagnostic testing and improved understanding of the ASD
phenotype. Additional conditions have already been reported
in association with an ASD phenotype, but to date none of
these have been evaluated in a large prospective cohort. Thus,
the possibility of a fourth (extended) tier of evaluation is a
distinct possibility in the near future. Alternatively, ad-
vances in technology may permit bundling of individual
tests into an extended, more readily accessible, and less-
expensive platform.
RECOMMENDATIONS
1. Accurate diagnosis: It is critically important that a firm
diagnosis of ASD is made before initiating any genetic
evaluation. Although the diagnosis of autism may seem
straightforward, many neurodevelopmental disorders
have overlapping phenotypes. The diagnosis should be
madebyaprofessionaltrainedinthediagnosisofautism.
The patient’s parents, siblings, and offspring may also
need to be evaluated. Objective criteria with the applica-
tion of generally accepted tools should be used. All per-
sons with apparent autism should have a formal audio-
gram to rule out a significant hearing loss.
2. Role of the primary care physician: All persons with au-
tism should have a designated primary care physician
(PCP).OftenthePCPwillbethefirstprofessionaltoraise
the question of ASD as a possible diagnosis. Depending
on training and comfort level, the PCP may be prepared
to make a diagnosis of an ASD. Alternatively, the PCP
may make a referral to a school team or mental health
professional for diagnostic confirmation. Recent guide-
lines from the American Academy of Pediatrics suggest
that the PCP obtain high-resolution chromosome stud-
ies(peripheralkaryotype)andFragileXstudieswhenthe
diagnosis of an ASD is confirmed. After clinical genetics
Schaefer et al.
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be prepared to partner in ordering, scheduling, and co-
ordination of recommended diagnostic testing.
3. Referral for clinical genetics evaluation: Defining the eti-
ologyofanASDcanbeofgreatbenefittothepatientand
family. Information gained from an identified etiology
can help with family counseling, medical management,
preventative health strategies, and empowerment of the
family.Clinicalgeneticistshavemuchtoofferinthispro-
cess beyond the initial assessments made by the PCP or
mental health professionals working with the individual
or family with ASD. As such, a genetic consultation
should be offered to all persons and families with ASDs.
Evaluations should be considered for any individual
along the full autism spectrum. The referring profes-
sional should discuss expectations and possible out-
comes of such an evaluation before making the referral.
The referring professional should be aware of what is
involved in such a consultation and the potential diag-
nostic yields and share this information with the patient
and family.
4. Tiered evaluation: The clinical genetic evaluation of an
individual with an ASD must be customized to the clin-
ical situation. A patient may be referred to the geneticist
with a specific diagnosis that is being considered—seek-
ing confirmation. Alternatively, a syndromic diagnosis
maybeapparenttothegeneticistupontheinitialvisit.In
either case, the diagnosis should be confirmed using ac-
cepted clinical criteria and laboratory testing (if avail-
able). Many recognizable syndromes have a firmly doc-
umented association with autism. For these conditions,
further investigation into the etiology of the ASD is un-
necessary. There are, however, genetic conditions that
havebeenreportedinassociationwithASDsinwhichthe
reported association is not as convincing. For patients
with these conditions, it is recommended that an etio-
logic evaluation for the ASD proceed as an independent
condition. Table 2 provides a partial list of these two
groups of conditions. If the clinical geneticist does not
identify a specific disorder upon the initial evaluation,
further testing can be accomplished as outlined in Table
1.
5. Counseling: Upon completion of the clinical genetics
evaluation, two groups of individuals will have been
identified: those with and those without an identifiable
major single etiology. Definitive counseling should be
provided to both groups. For those without an identifi-
able etiology, counseling should be provided for multi-
factorial inheritance. The best available published em-
piric recurrence risks for full siblings are 4% if the
affectedchildisagirland7%iftheaffectedchildisaboy.
Ifasecondchildhasautism,thereportedrecurrencerisk
has been from 25% to 50%. A reasonable synthesis of
published reports would be around 30%.
6. Follow-up: Clinical geneticists differ greatly in their de-
gree of involvement with patients after completion of
diagnostic consultations. Intervening changes in tech-
nologyandinphenotypesoftenaidinultimatelyobtain-
ing a diagnosis. At a minimum, periodic reevaluations
should be considered for patients in whom a definitive
etiologyisnotinitiallydiscovered.Thetimingofinterval
follow-ups should be a negotiation between the patient
and family, the PCP, and the geneticist.
Table 1
Template for the clinical genetic diagnostic evaluation of autism spectrum
disorders
Pre-evaluation
Confirmation of diagnosis of autism by trained professional using objective
criteria and tools
Sensory screening (complete audiogram)
Electroencephalogram—if clinical suspicion of seizures
Cognitive testing
Verify results of newborn screening
High-resolution chromosomal analysis and Fragile X studies may be
performed before referral
First tier
Initial evaluation to identify known syndromes or associated conditions
Examination with special attention to dysmorphic features
Should include Woods lamp evaluation
If specific diagnosis is suspected, proceed with targeted testing
Rubella titers—if clinical indicators present
“Standard” metabolic screening—if clinical indicators present and if
suspected condition was not assessed by newborn screening
Urine mucopolysaccharides and organic acids
Serum lactate, amino acids, ammonia, and acyl-carnitine profile
High-resolution chromosomal analysis—if not already performed
DNA for Fragile X—if not already performed
Second tier
Fibroblast karyotype if leukocyte karyotype is normal and clonal pigmentary
abnormalities are noted
Comparative genomic hybridization (chromosomal microarray)
a
MECP2 gene testing (females only)
PTEN gene testing (if the head circumference is 2.5 SD greater than the mean)
Third tier
Brain magnetic resonance imaging
Serum and urine uric acid
If elevated, Hypoxanthine-guanine phosphoribosyl transferase (HgPRT)
and Phosphoribosylpyrophosphate (PRPP) synthetase superactivity
testing
If low, purine/pyrimidine panel (uracil excretion, xanthine,
hypoxanthine)
Extracted from Schaefer GB and Mendelsohn NJ. Genetics evaluation for the
etiologic diagnosis of autism spectrum disorders. Genet Med 2008;10:4–12.
aAdvances in microarray technology will likely elevate aCGH to a first tier
study in the near future.
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Table 2
Partial list of genetic syndromes with a reported association with autism
No work-up indicated Autism evaluation indicated
Fragile X syndrome Apert syndrome
Rett syndrome Williams syndrome
Angelman syndrome Joubert syndrome
Prader-Willi syndrome Noonan syndrome
Smith-Lemli-Opitz syndrome Down syndrome
Smith-Magenis syndrome Turner syndrome
Tuberous sclerosis Neurofibromatosis
PTEN associated disorders
(Cowden syndrome, Bannayan-
Riley-Ruvalcaba syndrome)
Myotonic dystrophy,
Duchenne dystrophy
Shprintzen syndrome
(22q11 deletions)
Moebius anomalad
Sotos syndrome Cohen syndrome
CHARGE syndrome Oculo-auriculo-vertebral
spectrum
Hypomelanosis of Ito
Lujan-Fryns syndrome
De Lange syndrome
Extracted from Schaefer GB and Mendelsohn NJ. Genetics evaluation for the
etiologic diagnosis of autism spectrum disorders. Genet Med 2008;10:4–12.
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